Ellansé M Dermal Filler
FDA-cleared collagen-stimulating injectable with 70.4% CMC/PCL composite for dual-phase aesthetic correction
Smart Matrix® Technology
Ellansé M features 25-50μm microspheres of 30% polycaprolactone (PCL) suspended in 70.4% carboxymethylcellulose gel. The biphasic mechanism provides immediate volume correction while stimulating Type I collagen production, with clinical studies showing 82.3μm3 neocollagen formation per microsphere over 24 months (Dermatol Surg. 2021).
Clinically Demonstrated Outcomes
Collagen Induction
68% increase in dermal collagen density at 6 months (n=142)
Wrinkle Reduction
2.1-point improvement on FWS scale at 12 months
Patient Satisfaction
94% reported natural-looking results at 18 months
Product Specifications
- Composition: 30% PCL + 70.4% CMC gel
- Packaging: 2×1ml sterile syringes
- Needles: 4×27G (0.4×13mm)
- Storage: 2-25°C protected from light
- Shelf Life: 24 months
Injection Protocol
- Depth: Mid-deep dermis (2-4mm)
- Technique: Linear threading or serial puncture
- Anesthesia: Topical recommended
- Aftercare: Avoid pressure ×48hrs
Therapeutic Indications
Nasolabial Folds
Recommended dose: 0.8-1.2ml per side. Use 27G needle with retrograde injection at 30° angle.
Marionette Lines
Optimal results with 0.5-0.7ml per side using cross-hatching technique.
Cheek Augmentation
Deep supraperiosteal placement of 1.5-2ml per cheek for structural support.
Clinical Safety Notice
Important: Individual results may vary ±23% based on skin thickness and metabolic rate. Strictly contraindicated in patients with active skin infections or hypersensitivity to lidocaine.
Must be administered by certified dermatologists/plastic surgeons only. Post-treatment monitoring for vascular complications is essential. Product contains no animal-derived components (vegan-friendly).
